Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "BCG"

17 News Found

Decline in TB incidence by 16% from 237 per hundred thousand population in 2015 to 199 in 2022
News | September 25, 2024

Decline in TB incidence by 16% from 237 per hundred thousand population in 2015 to 199 in 2022

She reiterated the nation's commitment to eliminating TB as a public health problem by 2030 and ensuring a healthier future for all


Vijaya Medical and Educational Trust, Vadapalani  adopts AI-based monitoring technology
Digitisation | March 29, 2023

Vijaya Medical and Educational Trust, Vadapalani adopts AI-based monitoring technology

Vijaya Hospital, Chennai adopted Dozee’s AI-based contactless continuous remotemonitoring and early warning system to enhance patient safety


Merck’s pembrolizumab demonstrates improvement in distant metastasis
News | June 06, 2022

Merck’s pembrolizumab demonstrates improvement in distant metastasis

Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).


Bharat Biotech and Biofabri to develop and distribute novel TB vaccine
News | March 16, 2022

Bharat Biotech and Biofabri to develop and distribute novel TB vaccine

MTBVAC is a global public-private project that will be a milestone in the field of vaccinology


Rahul Guha to join Thyrocare Technologies as MD & CEO
People | February 07, 2022

Rahul Guha to join Thyrocare Technologies as MD & CEO

Rahul has spent almost 17 years at Boston Consulting Group (BCG) where he has led the Health Care & Life Sciences practice


Serum Life Sciences invests US $ 10 million in GreenLight Biosciences
Biotech | November 24, 2021

Serum Life Sciences invests US $ 10 million in GreenLight Biosciences

GreenLight Biosciences is a Boston-based biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible


Indian Pharma Market witnesses rise in volumes and prices in September.
News | October 28, 2021

Indian Pharma Market witnesses rise in volumes and prices in September.

Acute therapies continue to report strong growth compared to chronic ones.